Literature DB >> 3890187

Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors.

A J McEwan, B Shapiro, J C Sisson, W H Beierwaltes, D M Ackery.   

Abstract

Radioiodinated meta-iodobenzylguanidine, a recently developed radiopharmaceutical, has been shown to permit safe, noninvasive, sensitive, and specific scintigraphic location of pheochromocytomas of all types. The technique is especially efficacious in the case of extraadrenal primary lesions and locally recurrent and metastatic tumors. In addition to being taken up by pheochromocytomas, meta-iodobenzylguanidine may be used to image neuroblastomas, nonfunctioning paragangliomas, and carcinoid tumors. Lesions with high 131I-meta-iodobenzylguanidine uptake may respond to treatment with large doses of this radiopharmaceutical.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890187     DOI: 10.1016/s0001-2998(85)80022-2

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  25 in total

1.  Optimal tumor targeting by antibodies: development of a mathematical model.

Authors:  M J Chappell; G D Thomas; K R Godfrey; A R Bradwell
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

2.  Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine.

Authors:  F A Khafagi; B Shapiro; M Fischer; J C Sisson; R Hutchinson; W H Beierwaltes
Journal:  Eur J Nucl Med       Date:  1991

3.  Plasma gut hormone levels in 37 patients with pheochromocytomas.

Authors:  A I Vinik; B Shapiro; N W Thompson
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

4.  Nuclear medicine: metaiodobenzylguanidine in the diagnosis of pheochromocytoma and neuroblastoma.

Authors:  R S Hattner
Journal:  West J Med       Date:  1988-04

5.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

6.  Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.

Authors:  Shaunak Navalkissoor; Dona M Alhashimi; Ann-Marie Quigley; Martyn E Caplin; John R Buscombe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

7.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

Review 8.  Adverse reactions and drug interactions with radiopharmaceuticals.

Authors:  C B Sampson
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

Review 9.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

10.  131I-meta-iodobenzylguanidine scintigraphy in patients with neuroblastoma.

Authors:  S Hibi; S Todo; S Imashuku; T Miyazaki
Journal:  Pediatr Radiol       Date:  1987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.